Introduction
Coincidental with the evolution of higher-order primates roughly 20-30 myr ago, mutations in the uricase (urate oxidase) gene changed the end product of purine metabolism from allantoin to uric acid (UA). 1, 2 Together with further evolutionary changes, the result is that hominoids have serum UA levels that are regulated by a renal excretion/ reuptake system (reviewed in Rafey et al. 3 ) , and are at least 10-fold higher than in lower mammals. As homozygous mutation of the uricase gene is lethal in lower mammals, 2 it is reasonable to assume the presence of strong evolutionary pressures for the selection of the primary mutations and the retention of UA in higher primates. One possible explanation is the antioxidant properties of UA. Urate is an efficient scavenger of free radicals including several nitrogen-oxygen-based radicals such as peroxynitrite and its derivatives. [4] [5] [6] The beneficial effects of the radical scavenging properties of UA have been shown in a variety of pathophysiological conditions and appear to be particularly important in preventing inflammatory damage to the central nervous system (CNS) tissue. 7, 8 An alternative hypothesis is that elevated serum urate evolved to help maintain blood pressure in lowsalt dietary conditions encountered by early hominoids during the Miocene epoch. 9 This function of UA would be undesirable in modern humans with our high-salt diet and may contribute to the epidemic of cardiovascular disease and hypertension that plagues modern societies. Indeed there is evidence suggesting a pathogenic role for high UA levels in the development of hypertension, vascular disease and renal disease (for a review, see Johnson et al. 10 and Mene and Punzo
11
). It should be noted however that most studies in this field were conducted in patients pre-selected on the basis of cardiovascular risk ranging from early stage hypertension to fully developed metabolic syndrome (obesity, atherogenic dyslipidaemia, hypertension, insulin resistance).
Our recent clinical trial was conducted to evaluate the possibility that free-radical-induced CNS damage in multiple sclerosis (MS) patients may be ameliorated by raising serum UA levels. 12 Clinical data collected during multiple time points provided the opportunity to correlate the serum UA levels and blood pressure in 16 patients without any selection on the basis of vascular conditions. The results suggest that UA may not have a direct causative role in hypertension.
Patients and methods

Patient population
A total of 16 patients (15 women and 1 man) with relapsing remitting multiple sclerosis at the University of Pennsylvania MS Center were enrolled in the study. The average age of recruited patients was 43 (from 22 to 59), average weight 76 kg (from 60 to 101) and average disease duration since diagnosis 4.3 years (from 1 month to 13 years). Briefly, the study was randomised, double blinded, and of 1-year duration consisting of two arms: (1) a placebo-controlled crossover study consisting of 6 months placebo then 6 months of inosine; (2) inosine treatment for 12 months following baseline assessment. The protocol and consent form were approved by regulatory agencies and the institutional review boards of Thomas Jefferson University and the University of Pennsylvania. The trial was conducted in accordance with accepted guidelines. Trial Registration: clinicaltrials.gov, identifier: NCT00067327. Details of the study relevant to the disease modification objectives are published. 12 Treatment and clinical assessments Inosine and identical placebo capsules were prepared by JoMar Laboratories (Campbell, CA, USA) and contained either 500 mg inosine or fructose per capsule. The inosine dosage was initiated at 1-2 gm per day, and increased by 0.5 g per day at biweekly intervals until the target serum UA levels of 6-9 mg per 100 ml were achieved. For most patients the inosine dose required to maintain target UA levels was between 2 and 3 g per day. If blood UA levels exceeded 9 mg per 100 ml, the inosine dose was reduced. Blood work for CBC, BUN, creatinine and UA levels was initially conducted biweekly and later at monthly intervals. Systolic and diastolic blood pressure measurements were carried out by trained personnel using the OMRON Digital Blood Pressure Monitor, model HEM-907XL (OMRON, Bannockburn, IL, USA) maintained and calibrated annually and as needed by the Clinical Engineering Department personnel.
Statistical analysis
Evaluation of the significance of differences between parameters was performed using Student's t-test (Po0.05 was considered significant). Correlation coefficient was calculated using Correl.
Results
Inosine treatment effectively and sustainably increased serum UA levels in patients with MS (Table 1) . Average UA levels recorded during baseline/placebo and inosine phases were 4.2±0.8 and 7.1±1.7 mg per 100 ml respectively (Po0.0001). Inosine treatment was not found to modulate either systolic or diastolic blood pressure, with the blood pressure for 16 patients averaging 123 ± 11/78 ± 9 at 69 baseline/placebo visits and 123 ± 15/78 ± 9 for the same patients at 138 visits while on inosine treatment (P40.9).
Data for individual patients in arm 1 of the study consisted of 7-8 time points for each of both the placebo and treatment phases with the exception of patients 5 and 11 who withdrew from the study because of their development of kidney stones. The only male patient (no. 5) withdrew during the second month of treatment after three time points had been collected during the treatment phase whereas patient 11 withdrew during the first month of the treatment after only a single time point had been collected. Exceptionally high serum UA levels were recorded for both of these patients at their termination visits (10-15 mg per 100 ml); however no significant changes in blood pressure were noted. For the remaining five patients who completed the year-long arm 1 of the study we observed significant increases in serum UA levels (Po0.01) during the inosine treatment phase but no significant changes in blood pressure (Table 1) .
For patients enrolled in arm 2 of the study we had only a single reference point before the start of treatment, creating limitation for the statistical analysis of this group. For most patients in this group, 10-12 time points were collected during treatment phase with the exception of patients 2, 10 and 13. Patient 2 developed kidney stones during the first month of treatment. Patient 10 developed kidney stones during the eighth month of treatment. Treatment was interrupted for a month but later resumed. Blood pressure was slightly elevated, compared with baseline, at the time points coincidental with the development of kidney stones in both patients (141/95 in patient 2 and 137/74 in patient 10). Patient 13 withdrew after 2 months because of an unwillingness to continue with the study protocol (continue with regular hospital visits). Serum urate and blood pressure were low at a baseline for patient 13 (Table 1) . During first month of treatment UA was elevated to the target range (6.5 and 7.6 mg per 100 ml) whereas blood pressure remained low (107/68 and 110/70). At this patient's last visit, their serum UA level remained within target range (8.5 mg per 100 ml). However, their blood pressure was dramatically elevated (199/82).
No correlation between blood pressure (either systolic or diastolic) and UA was seen when pooled data for all patients were analysed (correlation coefficient o0.05 by Correl).
Discussion
Uric acid has known effects on certain aspects of immunity through both immunostimulatory and anti-inflammatory activities. For example, UA inactivates free radicals that contribute to the pathogenesis of CNS inflammation. [4] [5] [6] [7] [8] At the same time, numerous studies have linked high serum UA levels with increased blood pressure. Hyperuricaemia has been shown to maintain blood pressure in rats on a low-salt diet (for a review see Watanabe et al. 9 ). This raises the possibility that high UA levels may contribute to the pathogenesis of hypertension in humans, a concept supported by a number of studies showing an association between elevated serum UA levels and high blood pressure. [9] [10] [11] However most early studies were conducted either in rodent models, which have very different natural handling of the end purine metabolism, or in human populations already predisposed to vascular disorders, and thus do not provide a clear answer as to whether elevated serum UA is a cause or effect of such conditions. In this study, we used inosine, a natural metabolic precursor of UA, to raise serum urate levels in patients with MS to upper physiological levels of around 7-8 mg per 100 ml. This was achieved in most patients although we recorded several points at which UA concentrations had increased to levels considered hyperuricaemic. Overall increased serum UA levels were not associated with any significant changes in blood pressure. We did observe a few spikes in blood pressure during both placebo and inosine treatment phases. In some cases (for example, in patients 2 and 10) such transient increases were correlated with kidney stone formation requiring pain medication, whereas the others had no overt possible stimulus. No statistical correlation between elevated serum UA levels and increased blood pressure, either in paired comparison in individual patients in arm 1 of the study or in pooled data, was detected.
The prospect that serum UA levels may cause elevated blood pressure has generated considerable controversy in the literature. A number of animal and human studies have been reported in which increased serum UA levels were found to be associated not only with an increased risk for hypertension but also with a variety of cardiovascular diseases (reviewed in Watanabe et al., 9 Johnson et al., 10 and Mene and Punzo
11
). For example, rats treated with the urate oxidase inhibitor oxonic acid show increases in both serum UA level and blood pressure. [13] [14] However, unlike man, the rodent's excretion systems are not capable of handling large loads of urate. For example, uricase knockout mice die at several weeks of age because of the accumulation of UA throughout their bodies including precipitation in the kidneys.
1,2 Though urate crystals were not detected in the kidneys of rats treated with oxonic acid, other evidence of kidney injury was reported, 14 suggesting that the treatment may have pathological effects independent of the raised serum UA levels. In human adolescents, it has been shown that allopurinol treatment of newly diagnosed hyperuricaemia causes reduced blood pressure. 15 Allopurinol treatment also decreased the average serum UA levels in 30 patients with stage 1 hypertension from 7.0 to 4.2 mg per 100 ml and resulted in a small but significant reduction in blood pressure from 137/83 to 132/78 (Po0.05). 15 However, our data from the opposite perspective show that an increase in serum UA of similar magnitude (from 4.2 to 7.1) in individuals with normal blood pressure does not cause an elevation (P ¼ 0.9). Other studies have also failed to correlate serum UA levels and hypertension. For instance, a prospective, 8-year follow-up study among older men (47-81 years) without hypertension at the start of the study found Uric acid and blood pressure in MS patients S Spitsin et al no independent association between UA level and risk for developing hypertension during follow-up period. 16 In addition, rats on a high fructose diet developed hypertension without an increase in the serum UA levels. 17 There is one obvious difference between our study and others. Most studies have been performed in populations with underlying vascular problems including people with metabolic syndrome, who in addition to hypertension, also have obesity, dyslipidaemia and insulin resistance. We have studied non-ambulatory patients with MS who were not pre-selected for vascular problems. It should also be noted that the current study cohort was predominantly female. This is a reflection of the demographics of the patients from the University of Pennsylvania MS Center that met the inclusion criteria. Although we did not detect any increase in blood pressure in the single male patient in the study, our conclusions should formally be limited to women. Overall our results suggest that an elevation in serum UA is unlikely to be a direct trigger of hypertension in individuals without other predisposing factors.
